Last Updated on October 11, 2024 by The Health Master
The US Food and Drug Administration (USFDA) has granted approval for AbbVie’s Rinvoq (upadacitinib; 15 mg, once daily) to treat adults wsith active ankylosing spondylitis (AS).
The treatment is intended for AS patients who respond inadequately or are intolerant to one or more tumour necrosis factor (TNF) blockers.
A selective Janus kinase (JAK) inhibitor, Rinvoq is being analysed in various immune-mediated inflammatory ailments.
The latest approval is backed by safety and efficacy findings from the Phase III SELECT-AXIS 2 and Phase II/III SELECT-AXIS 1 clinical trials of Rinvoq.
The SELECT-AXIS 2 trial enrolled subjects who had an inadequate response or were intolerant to one or two biologic disease-modifying anti-rheumatic drugs (bDMARDs) while the SELECT-AXIS 1 enrolled subjects who were bDMARD-naïve and had an insufficient response or are not tolerant to a minimum of two nonsteroidal anti-inflammatory drugs (NSAIDs).
In both these trials, treatment with 15mg Rinvoq offered an ASAS40 response in a substantial proportion of subjects, meeting the primary endpoint versus placebo at week 14.
Furthermore, clinical responses were reported by the fourth week for ASAS40 in the SELECT-AXIS 2 trial.
Treatment with Rinvoq offered substantial improvement in AS signs and symptoms at week 14.
The latest USFDA approval for AS is the fifth indication for Rinvoq in chronic immune-mediated diseases.
AbbVie research and development senior vice-president and chief scientific officer Thomas Hudson said: “Ankylosing spondylitis is a debilitating disease that often affects younger adults and, over time, can result in lasting structural damage that can take an emotional toll on a patient’s life.
“This latest approval demonstrates another important step forward in our mission to advance the standards of care in rheumatic diseases.”
A chronic inflammatory musculoskeletal ailment, AS chiefly impacts the spine and causes debilitating symptoms of inflammatory back pain, stiffness and limited mobility.
In March this year, the USFDA approved Rinvoq for treating adults with moderate-to-severe active ulcerative colitis.
USFDA approves this oral heart disease drug
USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets
USFDA gives nod to Lupin for Desvenlafaxine ER tablets
USFDA authorises first C-19 diagnostic test using breath samples
USFDA gives approval to Aleor for Lidocaine & Prilocaine cream
USFDA gives nod to Indoco Remedies for Lacosamide injection
DCGI extends timeline for Pharma Firms to regularize 294 FDCs
Medical Degrees from Pakistan declared invalid by NMC
Himachal Pharma firms battle higher input costs
Medical Degrees from Pakistan declared invalid by NMC
USFDA approves this oral heart disease drug
E-Pharmacy market in India to grow at 45% in future: Report
Drug alert: 48 out of 1454 samples declared as NSQ in March 2022
Haryana ideal destination for Pharma Hub: Chief
Govt announces Indian Pharma and Medical Devices Awards 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
